A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
NCT05601128
Blood-Borne Infections, Communicable Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT Number: NCT04968717
Some individuals are able to spontaneously control HIV replication, the so-called 'elite controllers' (ECs). ECs are crucial for our understanding of HIV infection. While there is more and more evidence pointing towards a role of the innate immune system in elite control, no research has been performed on the role of innate trained immunity in elite control of HIV.
In this cross-sectional case-control study, we will study this role of trained immunity in HIV elite control by comparing ECs both to a non-HIV-infected first-degree relative, and to HIV patients who are not elite controllers. In addition, we will study whether HIV itself can induce a trained innate immunity phenotype.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
OLVG, Amsterdam, Netherlands
Rationale:
It remains unknown how some individuals spontaneously control HIV in the absence of antiretroviral medication, called HIV 'elite controllers' (ECs). ECs have been absolutely crucial to our current understanding of control of HIV replication. While research has mainly focused on the adaptive immune system, there is a vast amount of evidence indicating that the innate immune system is essential to HIV elite control.
Trained innate immunity can be expressed in terms of enhanced responsiveness of innate immune cells to a repeated trigger. This occurs through epigenetic remodeling after exposure to certain stimuli, such as beta-glucan, lipopolysaccharide (LPS) or the bacillus Calmette-Guérin (BCG) vaccine. Innate training results in an altered gene expression and metabolic reqiring on a cellular level, resulting in greater resistance against subsequent infection.
Both the impact of trained immunity on HIV infections and vice versa, the impact of HIV on trained immunity, are unknown. Our hypothesis is that ECs are natural hyper-responders to innate immune training triggers and that this aids in the HIV elite control phenotype.
Objectives:
Study design:
Cross-sectional case-control study.
For the primary objective, HIV elite controllers will be compared to ART-suppressed HIV patients who never have been elite controllers and first-degree relatives of HIV elite controllers will be compared to first-degree relatives of ART-suppressed HIV patients who have never been elite controllers.
For the secondary objectives, first, a system biology approach will be used in the comparison above. To determine the role of HIV in trained innate immunity we will compare people living with HIV (both controllers as non-controllers) to their respective family members.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
All participants:
HIV elite controllers:
HIV elite controllers in the 2000HIV that have an available first-degree relative. Definition of HIV elite controller is the same as in the 2000HIV, see definition on page 7 of the protocol and in the group description.
ART-suppressed people living with HIV:
As a control group, ART-suppressed people living with HIV in the 2000HIV that have an available first-degree relative will be included.
ART-suppressed people living with HIV need to apply to the following criteria to participate in the 2000HIV: ≥18 years, on cART ≥6 months with an HIV-RNA load <200 copies/mL.
For this 2000HIV-trained study, additional criteria for ART-suppressed people living with HIV are:
Eligible ART-suppressed people living with HIV will be matched by sex and age (max. 5-10 years apart), where possible. Similarity in family members between groups will also be pursued. That is why the HIV elite controllers and their family members will be enrolled first. Thereafter, the ART suppressed people living with HIV and their family members will be recruited and enrolled.
First-degree relatives:
Aside from the criteria for all participants mentioned above, there are no additional criteria for first-degree relatives of participants with HIV. If multiple first-degree relatives are available, siblings are preferred. If no sibling is available, then children >18 years. If no children >18 years, then parents. If there is still multiple options, same-sex will be preferred over different-sex relatives.
Time frame: 24 hour ex vivo experiment
Isolated monocytes and NK-cells will be stimulated ex vivo with a range of stimuli. Cytokines released in the supernatants will be measured by ELISA.
Time frame: 7 day ex vivo experiment
Isolated monocytes and NK-cells will be trained ex vivo and the innate training effect will be studied after restimulation with an unrelated stimulus on day 7. Cytokines released in the supernatant and intracellularly will be measured by ELISA.
Time frame: 1 year after sample collection
RNA in the cells will be analysed to gain a transcriptional signature.
Time frame: 1 year after sample collection
Epigenetic signatures will be studied by means of ChIP sequencing and ATAC sequencing.
Time frame: 1 year after sample collection
Circulating cells are phenotyped by menas of elaborate flow cytometry panels.
Time frame: Collected during visit
All groups
Time frame: Collected during visit
All groups
Time frame: Collected during visit
Only in first-degree relatives. Information on HIV patients already available from 2000HIV study (NCTNCT03994835).
Time frame: Collected during visit
Only in first-degree relatives. Information on HIV patients already available from 2000HIV study (NCTNCT03994835).
Time frame: Collected during visit
Only in first-degree relatives. Information on HIV patients already available from 2000HIV study (NCTNCT03994835).
Time frame: Collected during visit
Only in first-degree relatives. Information on HIV patients already available from 2000HIV study (NCTNCT03994835).
Radboud University Medical Center
Other
Acronym: 2000HIVTrained
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05601128
Blood-Borne Infections, Communicable Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT05471076
HIV-1-infection
Birmingham, Alabama, United States
View Trial DetailsNCT05405582
Communicable Diseases, Disease Attributes
Somkele, KwaZulu-Natal, South Africa
View Trial DetailsNCT04067869
Cytomegalovirus Infections, DNA Virus Infections
Bordeaux, France
View Trial Details